Compare · DHR vs TECH
DHR vs TECH
Side-by-side comparison of Danaher Corporation (DHR) and Bio-Techne Corp (TECH): market cap, price performance, sector, and recent activity on the wire.
Summary
- DHR operates in Industrials, while TECH operates in Health Care - the two are in different parts of the market.
- DHR is the larger of the two at $165.55B, about 14.5x TECH ($11.44B).
- TECH has been more active in the news (19 items in the past 4 weeks vs 18 for DHR).
- Both have 25 recent analyst ratings on file.
- Company
- Danaher Corporation
- Bio-Techne Corp
- Price
- -
- -
- Market cap
- $165.55B
- $11.44B
- 1M return
- +5.44%
- -
- 1Y return
- +7.19%
- -
- Industry
- Industrial Machinery/Components
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 18
- 19
- Recent ratings
- 25
- 25
Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company operates through three segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment provides mass spectrometers; cellular analysis, lab automation, and centrifugation instruments; microscopes; and genomics consumables. This segment also offers bioprocess technologies, consumables, and services; and filtration, separation, and purification technologies to the pharmaceutical and biopharmaceutical, food and beverage, medical, and life sciences companies, as well as universities, medical schools and research institutions, and various industrial manufacturers. The Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and molecular diagnostics products. This segment offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The Environmental & Applied Solutions segment offers instrumentation, consumables, software, services, and disinfection systems to analyze, treat, and manage ultra-pure, potable, industrial, waste, ground, source, and ocean water in residential, commercial, industrial, and natural resource applications. This segment also provides instruments, software, services, and consumables for various color and appearance management, packaging design and quality management, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.
Bio-Techne Corp
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, and diagnostics and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment provides biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment provides diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and nucleic acid analysis products for use in diagnostic or research applications, as well as instruments and process control products for hematology, blood chemistry, blood gases, and coagulation controls and reagents used in various diagnostic applications. It offers its products under R&D Systems, Novus Biologicals, Tocris Biosciences, ProteinSimple, Advanced Cell Diagnostics, and ExosomeDx brands. Bio-Techne Corporation has a clinical research collaboration with Carterra Inc. for the study of COVID-19 variants. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Latest DHR
- Executive Vice President Milosevich Gregory M sold $484,302 worth of shares (2,100 units at $230.62), decreasing direct ownership by 9% to 22,367 units (SEC Form 4)
- Executive Vice President Mcgrew Matthew exercised 17,385 shares at a strike of $88.24 and sold $4,097,452 worth of shares (17,385 units at $235.69) (SEC Form 4)
- SEC Form SCHEDULE 13G filed by Danaher Corporation
- Why the Next Edge in Antibody Discovery May Be What Labs Remember
- Integrated DNA Technologies and Aldevron Launch New mRNA Solutions to Simplify Base and Prime Editing
- Director Dewan Feroz was granted 144 phantom shares (SEC Form 4)
- Director Zerhouni Elias A. was granted 199 phantom shares (SEC Form 4)
- Director Filler Linda was granted 15 phantom shares (SEC Form 4)
- Director Stevens Raymond C was granted 153 phantom shares (SEC Form 4)
- Director List Teri was granted 13 phantom shares (SEC Form 4)
Latest TECH
- SEC Form 10-Q filed by Bio-Techne Corp
- Amendment: SEC Form SCHEDULE 13G/A filed by Bio-Techne Corp
- Bio-Techne Corp filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- BIO-TECHNE DECLARES DIVIDEND
- Chief Executive Officer Kelderman Kim covered exercise/tax liability with 2,385 shares, decreasing direct ownership by 3% to 80,509 units (SEC Form 4)
- CFO Hippel James converted options into 11,545 shares and covered exercise/tax liability with 5,096 shares, increasing direct ownership by 4% to 176,720 units (SEC Form 4)
- Amendment: CFO Hippel James converted options into 9,980 shares and covered exercise/tax liability with 4,423 shares, increasing direct ownership by 3% to 170,271 units (SEC Form 4)
- Amendment: PRESIDENT, PROTEIN SCIENCES Geist William converted options into 6,547 shares and covered exercise/tax liability with 2,019 shares, increasing direct ownership by 22% to 25,031 units (SEC Form 4)
- Amendment: Chief Executive Officer Kelderman Kim converted options into 21,736 shares and covered exercise/tax liability with 10,955 shares, increasing direct ownership by 15% to 82,894 units (SEC Form 4)
- Amendment: SVP - General Counsel Bohnen Shane converted options into 4,420 shares and covered exercise/tax liability with 1,366 shares, increasing direct ownership by 42% to 10,407 units (SEC Form 4)